CHINA HUAJUN GROUP LIMITED
中國華君集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 377)

(1) CHANGE OF DIRECTORS;
(2) CHANGE OF AUTHORISED REPRESENTATIVE AND PROCESS AGENT;
(3) REDESIGNATION OF DIRECTOR; AND
(4) CHANGE IN COMPOSITION OF BOARD COMMITTEES

The Board hereby announces that, with effect from 1 September 2026:

1. Mr. Yan has resigned as the Chairman, the executive Director and the Chief Executive Officer;

2. Dr. Li has resigned as the executive Director;

3. Ms. Wang has resigned as the executive Director;

4. Mr. Ding has resigned as the independent non-executive Director;

5. Ms. Zhu has resigned as the independent non-executive Director;

6. Mr. Li has been appointed as the Chairman, the executive Director and the Chief Executive Officer;

7. Ms. Tan has been appointed as the non-executive Director;

8. Ms. Shen has been appointed as the independent non-executive Director;

9. Dr. Gao has been appointed as the independent non-executive Director; and

10. Ms. Chen has been redesignated from an executive Director to a non-executive Director.

RESIGNATION OF DIRECTORS

The board (the "**Board**") of directors (the "**Director(s)**") of China Huajun Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby announces that, with effect from 1 September 2026:

1. Mr. Yan Ruijie ("**Mr. Yan**") has resigned as the chairman of the Board (the "**Chairman**"), the executive Director and the chief executive officer of the Company (the "**Chief Executive Officer**") due to his wish to devote more time on his other business engagements;

2. Dr. Li Dayi ("**Dr. Li**") has resigned as the executive Director due to his wish to devote more time on his other business engagements;

3. Ms. Wang Xiaomei ("**Ms. Wang**") has resigned as the executive Director due to her wish to devote more time on her other business engagements;

4. Mr. Ding Xingfu ("**Mr. Ding**") has resigned as the independent non-executive Director due to his wish to devote more time on his other business engagements; and

5. Ms. Zhu Fang ("**Ms. Zhu**") has resigned as the independent non-executive Director due to her wish to devote more time on her other business engagements (collectively, the "**Resignation**").

Each of Mr. Yan, Dr. Li, Ms. Wang, Mr. Ding and Ms. Zhu has confirmed that he/she has no disagreement with the Board and there is no matter relating to his/her resignation which needs to be brought to the attention of the shareholders of the Company (the "**Shareholders**") and The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Company would like to express its sincere gratitude towards their valuable contributions to the Group during their respective tenure of office.

APPOINTMENT OF DIRECTORS

The Board is pleased to announce that, with effect from 1 September 2026,

1. Mr. Li Gang ("**Mr. Li**") has been appointed as the Chairman, the executive Director and the Chief Executive Officer;

2. Ms. Tan Yanzi ("**Ms. Tan**") has been appointed as the non-executive Director;

3. Ms. Shen Shujiang ("**Ms. Shen**") has been appointed as the independent non-executive Director; and

4. Dr. Gao Xiang ("**Dr. Gao**") has been appointed as the independent non-executive Director.

The biographical details of Mr. Li and Ms. Tan are set out as follows:

Executive Director

Mr. Li Gang（**李剛**）, aged 63, has accumulated many years of working and corporate management experience in the fields of trading and financial technology. He founded Shenzhen Youbo Network Technology Co., Ltd.（深圳優博網路科技有限公司）and served as the general manager. He has also worked as the product director in Shanghai Mingchuang Software Technology Co., Ltd.（上海銘創軟件技術有限公司）, as the trust manager in Chongqing International Trust Co., Ltd.（重慶國際信託有限公司）and the trust manager in Zhongrong International Trust Co., Ltd.（中融信託有限公司）, and as the investment manager in Munsun Asset Management (Asia) Limited（麥盛資產管理（亞洲）有限公司）. From June 2020 to April 2025, Mr. Li served as the chairman and executive director of Enviro Energy International Holdings Limited, the shares of which are listed on the Stock Exchange with stock code 1102. Mr. Li is currently the director of Wonderland International Investment Holdings Limited（華德國際投資控股有限公司）, Longma International Technology Limited（龍馬國際科技有限公司）, respectively.

Mr. Li obtained a bachelor's degree in engineering from the University of Nanking（南京金陵大學）in 1984.

Non-executive Director

Ms. Tan Yanzi（**談燕子**）, aged 51, has many years of experience in the fields of power informatization, corporate management and investment. She is currently an investment consultant of Sunking Pacific Limited（賽晶亞太有限公司）since April 2024 and as a senior management of Beijing Huadian Xiangyun Software System Co., Ltd.*（北京華電祥雲軟件系統有限公司）since 2010.

Save as disclosed above, each of Mr. Li and Ms. Tan (i) has not held any directorships in the last three years preceding the date of this announcement in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not hold any other position with the Company or any other members of the Group; and (iii) has no other major appointments and professional qualifications.

Each of Mr. Li and Ms. Tan has entered into a service contract with the Company for an initial term of three years from 1 September 2026 and subject to retirement by rotation and re-election at the annual general meetings of the Company pursuant to the bye-laws of the Company. Each of Mr. Li and Ms. Tan will hold office until the next annual general meeting of the Company and then be eligible for re-election at such meeting in accordance with the Company's bye-laws. Mr. Li and Ms. Tan are entitled to receive an annual remuneration of HK$600,000 and HK$150,000 respectively, which is determined with reference to their duties and responsibilities as well as the Company's remuneration policy.

References are made to the announcement of the Company dated 26 August 2026 (the "**Announcement**") and the circular of the Company dated 4 August 2026 (the "**Circular**"). Unless otherwise defined, terms used herein shall have the same meanings as defined in the Announcement and the Circular.

Upon Completion, the Creditor will hold 94,000,000 shares of the Company, represent approximately 50.14% of the issued share capital of the Company. Since the Creditor is an investment holding company wholly-owned by Mr. Li, by virtue of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the "**SFO**"), Mr. Li will be deemed to be interested in the shares held by the Creditor upon Completion. The Company will make a further announcement upon Completion.

Save as disclosed above, each of Mr. Li and Ms. Tan does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed pursuant to the SFO.

Save as disclosed above, each of Mr. Li and Ms. Tan does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders (each as defined under the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")) of the Company. Save as disclosed above, Mr. Li and Ms. Tan have confirmed that there is no other information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules and there is no matter regarding their appointments that are required to be brought to the attention of the Shareholders and the Stock Exchange.

Independent non-executive Directors

The biographical details of each of Ms. Shen and Dr. Gao are set out as follows:

Ms. Shen Shujiang（沈蜀江）, aged 54, has extensive experience in corporate management, investment management, human resources management and securities affairs.

Ms. Shen previously served as securities affairs representative, director of the board office, board secretary and deputy general manager of Shenzhen Hongji (Group) Co., Ltd.*（深圳市鴻基（集團）股份有限公司）(currently know as Tunghsu Azure Renewable Energy Co., Ltd.（東旭藍天新能源股份有限公司）, a company used to be listed on the Shenzhen Stock Exchange (stock code: 000040)) from July 1995 to June 2016. She also served as board secretary and deputy general manager of Shenzhen Comix Group Co., Ltd.（深圳齊心集團股份有限公司）, a company listed on the Shenzhen Stock Exchange (stock code: 002301), from June 2016 to July 2019.

Ms. Shen served as an independent director of Vinner Health (Shenzhen) Co., Ltd. *（維尼健康（深圳）股份有限公司）, a company used to be listed on the National Equities Exchange and Quotations (the "**NEEQ**") (stock code: 835208), from September 2020 to August 2021, and of Guangzhou ChinaGDN Security Technology Co., Ltd.*（廣州競遠安全技術股份有限公司）, a company listed on the NEEQ (stock code: 870971), from January 2021 to January 2025. Since November 2022, Ms. Shen has been serving as an independent director of Shenzhen Minglida Precision Technology Co., Ltd.（深圳市銘利達精密技術股份有限公司）, a company listed on the Shenzhen Stock Exchange (stock code: 301268).

Ms. Shen obtained a bachelor's degree in business management from Jiangsu University of Science and Technology*（江蘇理工大學）in July 1994. She obtained the intermediate qualification in finance（中級金融資格）from the Shenzhen Professional Title Management Office*（深圳市職稱管理辦公室）in October 1998 and holds the Board Secretary Training Certificate issued by the Shenzhen Stock Exchange in September 1999.

Dr. Gao Xiang（高翔）, aged 62, a veteran in China's biotech industry, with decades of experience bridging the realms of biotech entrepreneurship and corporate governance. Dr. Gao founded GemPharmatech Co., Ltd.（江蘇集萃藥康生物技術股份有限公司）, a company listed on the Shanghai Stock Exchange (stock code: 688046), in December 2017 and has been serving as its chairman since then. Dr. Gao has been serving as an independent non-executive director of Alphamab Oncology, a company listed on the Stock Exchange (stock code: 9966) since June 2025.

Dr. Gao's early career was marked by his dedication to academic and laboratory research. From 1997 to 2000, he served as a research associate at the neuroscience center of University of North Carolina. Dr. Gao has been a professor at Nanjing University（南京大學）since March 2000, and was recognized a Yangtze River Scholar Distinguished Professor（長江學者獎勵計劃特聘教授）at the model animal research center in 2001, where he served as director from 2002 to 2012. Dr. Gao also served as the dean of the Nanjing Biomedical Research Institute of Nanjing University from 2009 to 2018, concurrently holding the position of director of the state key laboratory of pharmaceutical biotechnology. Beyond those roles, Dr. Gao was a director of the key laboratory of Model Animal and Disease Research（模式動物與疾病研究）of the Ministry of Education (MOE) from 2010 to 2015, and has been the director of the National Resource Center for Mutant Mice（國家遺傳工程小鼠資源庫）since 2002. Dr. Gao also holds multiple roles in academic societies, including, among others, member of the National Laboratory Animal Professional Committee（國家實驗動物專家委員會）, and member of the steering committee of the International Mouse Phenotyping Consortium（國際小鼠表型分析聯盟）. Dr. Gao has led numerous national research projects under, among others, the National 973 Program, 863 Program and Science and Technology Support Program. His outstanding contributions to scientific research have been recognized with prestigious awards, such as the National Science Fund for Distinguished Young Scholars（國家傑出青年科學基金）, the Special Prize of the MOE Award for Scientific and Technological Progress（教育部科技進步特等獎）and the Second Prize of the State Scientific and Technological Progress Award（國家科技進步二等獎）.

Dr. Gao obtained a bachelor's degree in zoology and a master's degree in biochemistry from Nanjing University in 1985 and 1988, respectively. He further obtained a Ph.D. in developmental biology and anatomy from Thomas Jefferson University in the United States in 1994. From 1994 to 1997, Dr. Gao successively conducted his postdoctoral research in Roche Institute of Molecular Biology and The Jackson Laboratory, both in the United States.

Save as disclosed above, each of Ms. Shen and Dr. Gao (i) has not held any directorships in the last three years preceding the date of this announcement in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not hold any other position with the Company or any other members of the Group; and (iii) has no other major appointments and professional qualifications.

Each of Ms. Shen and Dr. Gao has confirmed that (i) he/she met the independence criteria as set out in Rule 3.13 (1) to (8) of the Listing Rules; (ii) he/she has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his/her independence at the time of his/her appointment.

Each of Ms. Shen and Dr. Gao has entered into a letter of appointment with the Company for an initial term of three years from 1 September 2026 and subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the Company's bye-laws. Each of Ms. Shen and Dr. Gao will hold office until the next annual general meeting of the Company and then be eligible for re-election at such meeting in accordance with the Company's bye-laws. Each of Ms. Shen and Dr. Gao will receive a Director's fee of HK$150,000 per annum, which is determined with reference to their duties and responsibilities as well as the Company's remuneration policy.

As at the date of this announcement, each of Ms. Shen and Dr. Gao does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed pursuant to Part XV of the SFO. Each of Ms. Shen and Dr. Gao does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders (each as defined under the Listing Rules) of the Company. Save as disclosed above, each of Ms. Shen and Dr. Gao has confirmed that there is no other information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules and there is no matter regarding their appointment that is required to be brought to the attention of the Shareholders and the Stock Exchange.

The Board would like to express its warmest welcome to Mr. Li, Ms. Tan, Ms. Shen and Dr. Gao for joining the Board.

CHANGE OF AUTHORISED REPRESENTATIVE AND PROCESS AGENT

Following the resignation of Mr. Yan, he has ceased to be an authorized representative of the Company ("**Authorised Representative**") under Rule 3.05 of the Listing Rules and the authorised representative of the Company under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) for the acceptance of service of process and notices in Hong Kong (the "**Process Agent**"), with effect from 1 September 2026.

The Board is pleased to announce that Mr. Li has been appointed as the Authorised Representative and Process Agent with effect from 1 September 2026.

REDESIGNATION OF DIRECTOR

The Board hereby announces that Ms. Chen Yun ("**Ms. Chen**") has been redesignated from an executive Director to a non-executive Director with effect from 1 September 2026. Ms. Chen will cease to serve as a member of the Nomination Committee (as defined below).

The biographical details of Ms. Chen are as follows:

Ms. Chen Yun（陳雲）, aged 43, joined the Company in May 2017 and has been appointed as an Executive Director on 31 March 2023. She holds a bachelor degree in financial management from Yangzhou University（揚州大學）in the PRC. Prior to joining the Company, Ms. Chen has worked as the financial manager in several property development companies in Zhejiang and Jiangsu Provinces respectively. She served as the Company's financial controller of the Group's property segments. She has extensive experience in financial management.

Ms. Chen has entered into a service contract with the Company for an initial term of three years from 1 September 2026 and subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the Company's bye-laws. Ms. Chen will hold office until the next annual general meeting of the Company and then be eligible for re-election at such meeting in accordance with the Company's bye-laws. Ms. Chen will receive a Director's fee of HK$150,000 per annum, which is determined with reference to her duties and responsibilities as well as the Company's remuneration policy.

As at the date of this announcement, Ms. Chen beneficially holds 880 shares of the Company. Save as disclosed above, Ms. Chen does not have, and is not deemed to have any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations which are required to be disclosed pursuant to Part XV of the SFO. Ms. Chen does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders (each as defined under the Listing Rules) of the Company. Save as disclosed above, Ms. Chen has confirmed that there is no other information that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules and there is no matter regarding her redesignation that is required to be brought to the attention of the Shareholders and the Stock Exchange.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

Following the Resignation, with effect from 1 September 2026,

1. Mr. Yan has ceased to be member of the remuneration committee of the Company (the "**Remuneration Committee**");

2. Mr. Ding has ceased to be chairman of the Remuneration Committee and members of each of the audit committee of the Company (the "**Audit Committee**") and the nomination committee of the Company (the "**Nomination Committee**");

3. Ms. Zhu has ceased to be the chairlady of the Nomination Committee and members of each of the Audit Committee and the Remuneration Committee;

4. Ms. Chen has ceased to be member of the Nomination Committee; and

5. Mr. Mok Yi Kwo has ceased to be member of the Remuneration Committee.

The Board hereby announces that with effect from 1 September 2026,

1. Mr. Li has been appointed as the chairman of the Nomination Committee and a member of the Remuneration Committee; and

2. Ms. Tan has been appointed as a member of the Audit Committee;

3. Ms. Shen has been appointed as a member of each of the Remuneration Committee and the Audit Committee; and

4. Dr. Gao has been appointed as the chairman of the Remuneration Committee and a member of the Nomination Committee.

DEVIATION FROM THE CORPORATE GOVERNANCE CODE

Pursuant to code provision C.2.1 of the Corporate Governance Code as set forth in Appendix C1 to Listing Rules (the "**CG Code**"), the roles of chairman and chief executive should be separate and should not be performed by the same individual. As Mr. Li will be appointed as both the Chairman and the Chief Executive Officer, such practice deviates from code provision C.2.1 of the CG Code.

The Board believes that vesting the roles of Chairman and Chief Executive Officer in the same individual will facilitate the effective implementation of the Group's business strategies and enhance operational efficiency. Accordingly, the Board considers that the deviation from code provision C.2.1 of the CG Code is appropriate in the circumstances. In addition, the Board is structured in a manner that ensures effective checks and balances are in place, thereby safeguarding the interests of the Company and its Shareholders.

By order of the Board
China Huajun Group Limited
YAN Ruijie
Chairman, Chief Executive Officer and Executive Director

Hong Kong, 31 August 2026

As at the date of this announcement, the Board comprises Mr. Yan Ruijie, Ms. Chen Yun, Dr. Li Dayi and Ms. Wang Xiaomei as executive Directors; and Mr. Mok Yi Kwo, Mr. Ding Xingfu and Ms. Zhu Fang as independent non-executive Directors.